A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Active, not recruiting · Phase 3 · NCT04002297
Conditions: Mantle Cell Lymphoma, Non-Hodgkin Lymphoma
At a glance
- Research payments reported, 2025
- $613,931
- U.S. investigators named
- 14
- Sites paid
- 14
- Planned or actual enrollment
- 510
About the trial
- Sponsor
- BeOne Medicines
- Tested
- zanubrutinib (drug), bendamustine (drug), rituximab (drug)
- Dates
- Started 2019-08-20; completion 2031-09-30
- Results posted
- Not yet
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
From ClinicalTrials.gov, last updated 2026-09-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $613,931 in research payments for this study in 2025 (239 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lauren C. Pinter-brown, MD Hematology & Oncology · Los Angeles, CA
- Sarah E. Tomassetti, M.D. Hematology & Oncology · Torrance, CA
- Seo-hyun Kim, M.D. Hematology · Chicago, IL
- Yasmin H. Karimi, M.D. Hematology · Ann Arbor, MI
- Patrick W. Cobb, M.D. Hematology & Oncology · Billings, MT
- Edwin C. Kingsley, MD Hematology & Oncology · Las Vegas, NV
- Jon E. Arnason, MD Internal Medicine · New York, NY
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Jonah Shulman Medical Oncology · New York, NY
- Natasha C. Edwin, M.D. Internal Medicine · Portland, OR
- Cyrus M. Khan, M.D. Hematology & Oncology · Erie, PA
- Preetesh Jain, MD Hematology · San Antonio, TX
- Donald P. Quick, MD Hematology & Oncology · Lubbock, TX
- Stephen D. Smith, M.D. Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $258,918
- University of Michigan Health System, MI $90,460
- Covenant Health - Joe Arrington Cancer Research Treatment Center $51,386
- University of Washington Medical Ctr, WA $46,360
- Biomedical Research Alliance of New York, LLC $37,914
- Allegheny Singer Research Institute $33,423
- Uci Health-Orange, CA $31,221
- Clinical Research Alliance, Inc. $17,349
- Providence Portland Medical Center, OR $13,528
- Intermountain Health St Vincent Regional Hospital, MT $10,985
- Rush University Medical Center, IL $10,351
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $5,000
- Beth Israel Deaconess Medical Center, MA $3,888
- Comprehensive Cancer Centers of Nevada - Central Valley $3,150
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.